Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: Where do we stand?

Leukemia and Lymphoma

Volumn 54, Issue 11, 2013, Pages 2351-2364

  Rosenquist, Richard ^a   Cortese, Diego ^a   Bhoi, Sujata ^a   Mansouri, Larry ^a   Gunnarsson, Rebeqa ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Chronic lymphocytic leukemia; Gene mutations; Genetic aberrations; Predictive markers; Prognostic index; Prognostic markers; RNA based markers

Indexed keywords

B LYMPHOCYTE RECEPTOR; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CD38 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; LIPOPROTEIN LIPASE; MICRORNA; NOTCH1 RECEPTOR; PROTEIN; PROTEIN BCL 2; PROTEIN BCL 3; PROTEIN KINASE ZAP 70; PROTEIN P53; PROTEIN TCL1; RNA; THYMIDINE KINASE; TUMOR MARKER; UNCLASSIFIED DRUG;

BACULOVIRAL IAP REPEAT CONTAINING 3 GENE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 12; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHROMOSOME DELETION 13; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CLL UPREGULATED GENE 1; COMPLEMENTARITY DETERMINING REGION; DIAGNOSTIC VALUE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENE MUTATION; GENOMIC INSTABILITY; HIGH RISK PATIENT; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; LYMPHOCYTE COUNT; LYMPHOCYTE DOUBLING TIME; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SF3B1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SPLICEOSOME; TREATMENT RESPONSE; TRISOMY 12; TUMOR VOLUME;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879651228     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.783913     Document Type: Review

References (164)

1. Binet JL, AuquierA, Dighiero G, et al. Anewprognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
2. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
3. Hamblin TJ. Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2007;20:455-468.
4. Montserrat E, Sanchez-Bisono J, Vinolas N, et al. Lymphocyte doubling time in chronic lymphocytic leukaemia: Analysis of its prognostic significance. Br J Haematol 1986;62:567-575.
5. HallekM, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;1 11:5446-5456.
6. Fasola G, Fanin R, Gherlinzoni F, et al. Serum LDH concentration in non-Hodgkin?s lymphomas. Relationship to histologic type, tumor mass, and presentation features. Acta Haematol 1984;72:231-238.
7. Lee JS, Dixon DO, ICantarjian HM, et al. Prognosis of chronic lymphocytic leukemia: A multivariate regression analysis of 325 untreated patients. Blood 1987;69:929-936.
8. Rossi D, Cern M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 2008;142:202-215.
9. Hallek M, Wanders L, Ostwald M, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996;22:439-447.
10. Tsimberidou AM, Wen 5, O?Brien 5, et al. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in2, l26patients: 20 years of experience at theUniversity of Texas M.D. Anderson Cancer Center. J din Oncol 2007;25:4648-4656.
11. Gentile M, Cutrona G, Neri A, Molica 5, Ferrarini M, Morabito E Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica 2009; 94:887-888.
12. Di Raimondo F, Giustolisi R, Lerner 5, et al. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with iludarabine. Ann Oncol 200 1; 12 :621-625.
13. Magnac C, Porcher R, Davi F, et al. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia 2003; 17: 133-137.
14. Matthews C, Catherwood MA, Morris TC, et al. Serum TIC levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. Eur Haematol 2006;77:309-317.
15. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.
16. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854.
17. Ghia P, Stamatopoulos IC, Belessi C, et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia 2007;21:1-3.
18. Langerak AW, Day F, Ghia P, et al. Immunoglobulin sequence analysis and prognostication in CLL: Guidelines from the ERIC review board for reliable interpretation of problematic cases. Leukemia 201 1;25:979-984.
19. ICrober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100: 1410-1416.
20. Lin IC, Sherrington PD, Dennis M, et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002;100:1404-1409.
21. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177-1184.
22. Tobin G, Thunberg U, Laurell A, et al. Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome. Haematologica 2005;90:465-469.
23. Hamblin TJ, Davis ZA, Oscier DG. Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia -long-term follow up of patients with different percentages of mutations. Br J Haematol 2008; 140:320-323
24. Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99:2262-2264.
25. Bomben R, Dal Bo M, Capello D, et al. Comprehensive characterization of IGHV3-21-expressing B-Cell chronic lymphocytic leukemia: An Italian multicenter study. Blood 2007;109:2989-2998.
26. Ghia EM, Jam 5, Widhopf GF 2nd, et al. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood 2008;111:5101-5108.
27. Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 2006;107:2889-2894.
28. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemiasutilizingtheVH3-21 gene displayhighlyrestrictedVlambda2-14 gene use and homologous CDR3s: Implicating recognition of a common antigen epitope. Blood 2003;101:4952-4957.
29. Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004;104:2879-2885.
30. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
31. Rosen A, Murray F, Evaldsson C, Rosenquist R. Antigens in chronic lymphocytic leukemia-1mplications for cell origin and leukemogenesis. Semin Cancer Biol 2010;20:400-409.
32. Messmer BY, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004;200:519-525.
33. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 2007;109: 259-270.
34. Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-Cell receptors in one-third of chronic lymphocytic leukemia: A molecular classification with implications for targeted therapies. Blood 2012;119:4467-4475.
35. Bomben R, Dal Bo M, Capello D, et al. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: Results from an Italian multicentre study. Br J Haematol 2009; 144:492-506.
36. Ghia P, Stamatopoulos K, Belessi C, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: The lesson of the IGHV3-21 gene. Blood 2005; 105:1678-1685.
37. Dohner H, Stilgenbauer 5, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910-1916.
38. Gunnarsson R, Mansouri L, Rosenquist R. Exploring the genetic landscape in chronic lymphocytic leukemia using high-resolution technologies. Leuk Lymphoma 2013 Feb 28.
39. Rossi D, Rasi 5, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013;121:1403-1412.
40. Zenz I, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37-50.
41. Pospisilova 5, Gonzalez D, Malcikova J, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012;26:1458-1461.
42. Gunnarsson R, Isaksson A, Mansouri M, et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: A high-resolution genomic screening of newly diagnosed patients. Leukemia 2010;24:211-215.
43. Haferlach C, Dicker F, Schnittger 5, et al. Comprehensive genetic characterization of CLL: A study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007;21:2442-2451.
44. Kujawski L, Ouillette P, Erba H, et al. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood 2008;112:1993-2003.
45. Mayrc, SpeicherMR, KoflerDM, etal. Chromosomaltranslocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006;107:742-751.
46. Van Den Neste E, Robin V, Francart J, et al. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-Cell chronic lymphocytic leukemia patients treated with cladribine. Leukemia 2007;21:1715-1722.
47. Fabbri G, Rasi 5, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: Role ofNOTCH1 mutational activation. J Exp Med 2011;208:1389-1401.
48. Puente XS, Pinyol M, QuesadaV, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101-105.
49. Quesada V Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012;44:47-52.
50. Rossi D, Fangazio M, Rasi 5, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012;1 19:2854-2862.
51. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365:2497-2506.
52. Mansouri L, Cahill N, Gunnarsson R, et al. NOTCH 1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia. Leukemia 2013;27:5 12-514.
53. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-Cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990;323:720-724.
54. Gunnarsson R, MansouriL, IsakssonA, et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica 2011;96:1161-1169.
55. Stilgenbauer 5, Liebisch P, James MR, et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders. Proc Natl Acad Sci USA 1996;93:1 1837-11841.
56. Taylor AM, Metcalfe TA, Thick J, et al. Leukemia and lymphoma in ataxia telangiectasia. Blood 1996;87:423-438.
57. Austen B, Powell JE, Alvi A, et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005;106:3175-3182.
58. Bullrich F, Rasio D, Kitada 5, et al. ATM mutations in B-Cell chronic lymphocytic leukemia. Cancer Res 1999;59:24-27.
59. Rossi D, Fangazio M, Gaidano G. The spectrum of genetic defects in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis 2012;4:E2012076.
60. Dohner H, Stilgenbauer 5, James MR, et al. llq deletions identify a new subset of B-Cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89:2516-2522.
61. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010;376:1 164-1174.
62. Mosca L, Fabris 5, Lionetti M, et al. Integrative genomics analyses reveal molecularly distinct subgroups of B-Cell chronic lymphocytic leukemia patients with 13q14 deletion. Clin Cancer Res 20 10; 16:5641-5653
63. Ouillette P, Erba H, Kujawski L, et al. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res 2008;68:1012-1021.
64. Liu Y, Corcoran M, Rasool 0, et al. Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene 1997; 15:2463-2473
65. LiuY, Grander D, Soderhall 5, et al. Retinoblastoma gene deletions in B-Cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 1992;4:250-256.
66. Liu Y, Szekely L, Grander D, et al. Chronic lymphocytic leukemia cells with allelic deletions at 13q14 commonly have one intact RB1 gene: Evidence for a role of an adjacent locus. Proc Natl Acad Scm USA 1993;90:8697-8701.
67. Calm GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miRl5 and miRl6 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Scm USA 2002;99:15524-15529.
68. Cimmino A, Calm GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Scm USA 2005;102: 13944-13949.
69. Mian M, Rinaldi A, Mensah AA, et al. Del(13q14.3) length matters: An integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. Hematol Oncol 2012;30:46-49.
70. Parker H, Rose-Zerilli MJ, Parker A, et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia 2011;25:489-497.
71. Van Dyke DL, Shanafelt TD, Call TG, et al. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol 2010;148:544-550. Prognostic markers in CLL 2363
72. Xu-Monette ZY, Medeiros U, Li Y, et al. Dysfunction of the TPS3 tumor suppressor gene in lymphoid malignancies. Blood 2012;1 19:3668-3683.
73. Dicker F, Herholz H, Schnittger S, et al. The detection of TPS3 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009;23:1 17-124.
74. Forconi F, Rinaldi A, Kwee I, et al. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with l7p deletion. Br J Haematol 2008; 143:532-536.
75. Malcikova J, Smardova J, Rocnova L, et al. Monoallelic and biallelic inactivation of TPS3 gene in chronic lymphocytic leukemia: Selection, impact on survival, and response to DNA damage. Blood 2009;1 14:5307-53 14.
76. Zainuddin N, Murray F, Kanduri M, et al. TP53 mutations are infrequent in newly diagnosed chronic lymphocytic leukemia. Leuk Res 2011;35:272-274.
77. Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term follow-up. Blood 2008;112:3322-3329.
78. Zenz I, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473-4479.
79. Zenz T, Habe 5, Denzel I, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): Dissecting the contribution of l7p deletion, TP53 mutation, pS3-p2l dysfunction, and miR34a in a prospective clinical trial. Blood 2009; 114:2589-2597.
80. Zenz T, Vollmer D, Trbusek M, et al. TP53 mutation profile in chronic lymphocytic leukemia: Evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 2010;24:2072-2079.
81. Lozanski G, Heerema NA, Flinn JW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103:3278-3281.
82. Stilgenbauer 5, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994-4001.
83. CatovskyD, Richards S, Matutes E, et al. Assessment offludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 2007;370:230-239.
84. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase 11I Trial E2997. 1 Clin Oncol 2007;25:799-804.
85. Stilgenbauer 5, Eichhorst BF, Busch R, et al. Biologic and clinical markers for outcome after fludarabine (F) or F plus cyclophosphamide (FC) -comprehensive analysis of the CLL4 trial of the GCLLSG. Blood 2008;1 12(Suppl. 1): Abstract 2089.
86. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-Cell leukemias. Blood 1995;85:1580-1589.
87. Fenaux P, Preudhomme C, Lai JL, et al. Mutations of the p53 gene in B-Cell chronic lymphocytic leukemia: A report on 39 cases with cytogenetic analysis. Leukemia 1992;6:246-250.
88. Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006;20:1441-1445.
89. Juliusson G, Robert KH, Ost A, et al. Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma. Blood 1985;65:134-141.
90. Juliusson G, Merup M. Cytogenetics in chronic lymphocytic leukemia. Semin Oncol 1998;25:19-26.
91. Schwaenen C, Nessling M, Wessendorf 5, et al. Automated array-based genomic profiling in chronic lymphocytic leukemia: Development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci USA 2004;101:1039-1044.
92. Sellmann L, Gesk 5, Walter C, et al. Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia. Br J Haematol 2007;138:217-220.
93. Ibbotson R, Athanasiadou A, Sutton LA, et al. Coexistence of trisomies of chromosomes 12 and 19 in chronic lymphocytic leukemia occurs exclusively in the rare IgG-positive variant. Leukemia 2012;26:170-172.
94. Athanasiadou A, Stamatopoulos K, Gaitatzi M, et al. Recurrent cytogenetic findings in subsets of patients with chronic lymphocytic leukemia expressing IgG-switched stereotyped immunoglobulins. Haematologica 2008;93:473-474.
95. Chapiro E, Radford-Weiss I, Bastard C, et al. The most frequent t(14;19)(q32;q13)-positive B-Cell malignancy corresponds to an aggressive subgroup of atypical chronic lymphocytic leukemia. Leukemia 2008;22:2123-2127.
96. Martin-Subero JI, Ibbotson R, Klapper W, et al. A comprehensive genetic and histopathologic analysis identifies two subgroups of B-Cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation. Leukemia 2007;21:1532-1544.
97. Roos G, KroberA, Grabowski P, et al. Shorttelomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 2008;111:2246-2252.
98. Edelmann J, Holzmann K, Miller F, et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 2012;120:4783-4794.
99. Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011;144:27-40.
100. Vilimas T, Mascarenhas J, Palomero T, et al. Targeting the NFkappaB signaling pathway in Notchi-Induced I-Cell leukemia. Nat Med 2007 13:70-77
101. Vilimas T, Mascarenhas J, Palomero T, et al. Targeting the NFkappaB signaling pathway in Notchi-Induced I-Cell leukemia. Nat Med 2007;13:70-77.
102. Santos MA, Sarmento LM, Rebelo M, et al. Notchi engagement by Delta-like-1 promotes differentiation of B lymphocytes to antibody-secreting cells. Proc Natl Acad Sci USA 2007;104:15454-15459.
103. Rosati E, Sabatini R, Rampino G, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009;113:856-865.
104. Del Giudice I, Rossi D, Chiaretti 5, et al. NOTCH1 mutations in + 12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of+ 12 CLL. Haematologica 2012;97:437-441.
105. BalattiV, BottoniA, PalamarchukA, et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012;119:329-331.
106. Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical significance ofNOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013;121:468-475.
107. Rossi D, Rasi 5, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012;119:521-529.
108. Villamor N, Conde U, Martinez-Trillos A, et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 2012 Dec 6.
109. Rossi D, Rasi S, Spina V, et al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br 1 Haematol 2012;158:426-429.
110. Sportoletti P, Baldoni 5, Cavalli U, et al. NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CUU. Br J Haematol 20 10; 15 1:404-406.
111. Wahl MC, Will CU, Uuhrmann R. The spliceosome: Design principles of a dynamic RNP machine. Cell 2009; 136:701-718.
112. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: Association with progression and fludarabine-refractoriness. Blood 201 1;118:6904-6908.
113. Rossi D, Deaglio 5, Dominguez-Sola D, et al. Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. Blood 2011;118:4930-4934.
114. Buggins AG, Pepper C, Patten PE, et al. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cellsviaNF-kappaB activation and denovogenetranscription. Cancer Res 2010;70:7523-7533.
115. Herishanu Y, Perez-Galan P, Uiu D, et al. The lymph node microenvironment promotes B-Cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563-574.
116. Malavasi F, Deaglio 5, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene familyin physiology and pathology. Physiol Rev 2008;88:841-886.
117. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023-1029.
118. Thunberg U, Johnson A, Roos G, et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 2001;97:1892-1894.
119. Ghia P, Guida G, Stella 5, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101:1262-1269.
120. Van derVeerMS, de Weers M, Van Kessel B, et al. Towards effective immunotherapy of myeloma: Enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Raematologica 2011;96:284-290.
121. Chan AC, Iwashima M, Iurck CW, et al. ZAP-70: A 70 kd protein-tyrosine kinase that associates with the ICR zeta chain. Cell 1992;1:649-662
122. Negishi I, Motoyama N, Nakayama K, et al. Essential role for ZAP-70 in both positive and negative selection of thymocytes. Nature 1995;376:435-438.
123. Scielzo C, Camporeale A, Geuna M, et al. ZAP-70 is expressed by normal and malignant human B-Cell subsets of different maturational stage. Leukemia 2006;20:689-695.
124. Chen L, Widhopf G, Ruynh L, et al. Expression of ZAP-70 is associated with increased B-Cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100:4609-4614.
125. Efremov DG, Gobessi 5, Longo PG. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. Autoimmun Rev 2007;7:102-108.
126. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-1647.
127. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable -region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775.
128. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105-111.
129. Wiestner A, Rosenwald A, Barry IS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-4951.
130. Krober A, Bloehdorn J, Rather 5, et al. Additional genetic high-risk features such as llq deletion, l7p deletion, and V3-21 usage characterize discordance of ZAP-70 and yR mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006;24:969-975.
131. Wang CS, Hartsuck J, McConathy WJ. Structure and functional properties of lipoprotein lipase. Biochim Biophys Acta 1992;1123:1-17.
132. Mamputu JC, Renier G. Differentiation of human monocytes to monocyte-derived macrophages is associated with increased lipoprotein lipase-Induced tumor necrosis factor-alpha expression and production: A process involving cell surface proteoglycans and protein kinase C. Arterioscler Thromb Vasc Biol 1999;19:1405-1411.
133. Mansouri M, Sevov M, Fahlgren E, et al. Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity. Leuk Res 2010;34:301-306.
134. Klein U, Th Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625-1638.
135. Reintel D, Kienle D, Shehata M, et al. Righ expression of lipoprotein lipase in poor risk B-Cell chronic lymphocytic leukemia. Leukemia 2005;19:1216-1223.
136. Kaderi MA, Kanduri M, Buhl AM, et al. LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia. Raematologica 2011;96: 1153-1160.
137. Kienle D, Benner A, Laufle C, et al. Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. Raematologica 2010;95:102-109.
138. Oppezzo P, Vasconcelosy, Settegrana C, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005;106:650-657.
139. Van Bockstaele F, Pede V, Janssens A, et al. Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia. Clin Chem 2007;53:204-212.
140. van?tVeerMB, BrooijmansAM, LangerakAW, et al. The predictive value oflipoprotein lipase for survival in chronic lymphocytic leukemia. Raematologica 2006;91:56-63.
141. Sevov M, Rosenquist R, Mansouri L. RNA-based markers as prognostic factors in chronic lymphocytic leukemia. Expert Rev Rematol 2012;5:69-79.
142. Buhl AM, Jurlander L Jorgensen PS, et al. Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia. Blood 2006;107:2904-2911.
143. Buhl AM, Jurlander J, Geisler CH, et al. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. Eur J Raematol 2006;76:455-464.
144. Josefsson P, Geisler CH, Leffers R, et al. CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood 2007;109:4973-4979.
145. Stamatopoulos B, Meuleman N, De Bruyn C, et al. A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients. PLoS One 2010;5. pu: E12780.
146. Gonzalez D, Else M, Wren D, et al. CLLU1 expression has prognostic value in CLL after first-line therapy in younger patients and those with mutated IGHV genes. Raematologica 2013;98:274-278.
147. Buhl AM, James DF, Neuberg D, et al. Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia. Eur J Raematol 2011;86:405-411.
148. Calm GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-1801.
149. Fulci V, Chiaretti 5, Goldoni M, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007;109:4944-4951.
150. Marton 5, Garcia MR, Robello C, et al. Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 2008;22:330-338.
151. Pekarsky Y, Santanam U, Cimmino A, et al. Icli expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006;66:11590-11593.
152. Rossi 5, Shimizu M, Barbarotto E, et al. microRNA fingerprinting of CLL patients with chromosome l7p deletion identify a miR-21 score that stratifies early survival. Blood 2010;116:945-952.
153. Stamatopoulos B, Meuleman N, Raibe-Kains B, et al. microRNA29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009;113:5237-5245.
154. Zenz T, Mohr J, Eldering E, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009;113:3801-3808.
155. Zhou K, Yi 5, Yu Z, et al. MicroRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:1 155-1161.
156. Neilson JR, Zheng GX, Burge CB, et al. Dynamic regulation of miRNA expression in ordered stages of cellular development. Genes Dev 2007;21:578-589.
157. Raferlach C, Dicker F, Weiss T, et al. Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters. Genes Chromosomes Cancer 2010;49:851-859.
158. Wierda WG, O?Brien 5, Wang X, et al. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 2011;29:4088-4095.
159. Pepper C, Majid A, Lin TT, et al. Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Raematol 20 12; 156:499-507
160. Onkologiskt centrum, Södra sjukhusregionen, 2008-2010. National guidelines for investigation and treatment of chronic lymphocytic leukemia. Available from: Http://www.oc.gu.se/pdf/KLL-Nationella-Riktlinjer-20060601 .pdf
161. British Committee for Standards in Raematology. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Available from: Http://www.bcshguidelines. com/documents/Revised-CLL- guidelinejuly-13-vl .pdf
162. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006;24:4634-4641.
163. Stilgenbauer 5, Sander 5, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia: Acquisition of high-risk genomic aberrations associated with unmutated VR, resistance to therapy, and short survival. Raematologica 2007;92:1242-1245.
164. Strefford J, Sutton LA, Baliakas P, Agathangelidis A, Maléfková J, Plevova K, Scarfó L, Davis Z, Stalika E, Cortese D, Cahill N, Bredo Pedersen L, Francia di Celle P, Tzenou T, Geisler C, Panagiotidis P, Langerak AW, Chiorazzi N, Pospisilova 5, Oscier D, Davi F, Belessi C, Mansouri L, Ghia P, Stamatopoulos K, Rosenquist R. Distinct patterns